Biotechnology
Health
Pharmaceutical
Arena Pharmaceuticals
$53.209876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$53.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.73 (-1.35%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ARNA and other stocks, options, ETFs, and crypto commission-free!
About
Arena Pharmaceuticals, Inc. Common Stock, also called Arena Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. Read More It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
Employees
194
Headquarters
San Diego, California
Founded
1997
Market Cap
2.67B
Price-Earnings Ratio
4.39
Dividend Yield
0.00
Average Volume
553.09K
High Today
$53.61
Low Today
$52.30
Open Price
$53.26
Volume
206.66K
52 Week High
$58.00
52 Week Low
$31.97
Collections
Biotechnology
Health
Pharmaceutical
Biopharmaceutical
Technology
News
CNBCMay 17
Cramer's lightning round: Arena Pharmaceuticals, Yext, IAC, and more
Arena Pharmaceuticals Inc.: "We like Arena. We've liked it. I know it's speculative. It's O.K. for a spec, as long as you're willing to understand that this is not Merck. " IAC/InterActiveCorp.: "I thought that was an amazing quarter. I think that company is so inexpensive, I frankly don't even understand it. I say it's a buy, buy, buy." Yext inc.: "I like Y-E-X-T ... I think the stock is a buy." Davita Inc.: "Why didn't you just go into Abbott Labs? I mean honestly, Davita is way too volatile for me. I ...
Yahoo FinanceMay 13
All You Need to Know About Arena Pharmaceuticals Rating Upgrade to Buy
Harris (HRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. Arena Pharmaceuticals (ARNA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current ...
Yahoo FinanceMay 13
Arena Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: UBS Global Healthcare Conference on Monday, May 20 , at 8:30 AM EDT in New York City , at in RBC Capital Markets Global Healthcare Conference on Tuesday, May 21 , at 2:05 PM EDT in New York City , at in Berenberg USA Conference on Wednesday, May 22 , at 2:45 PM EDT in Tarrytown, NY A live audio webcast of the UBS and ...
Price Paid on Robinhood
39% Higher
Right Now
52 Week Low
$31.97
Average Price Paid
$38.22
52 Week High
$58.00
Earnings
-$0.82
$4.08
$8.99
$13.89
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 5, After Hours